Cortico-subcortical dynamics in Parkinson's disease

Part I Cortico-Subcortical Circuits and Parkinson’s Disease 1 Leading Toward a Unified Cortico-basal Ganglia Functional Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Shannon R. Blume and Kuei Y. Tseng 2 Modeling Parkinson’s Disease: 50 Years Later . . . . . . . . . . . . . . . . . 23 Gloria E. Meredith and Kuei Y. Tseng Part II Physiological Studies of the Cortico-subcortical Dynamics and Parkinson’s Disease 3 Phasic Dopaminergic Signaling: Implications for Parkinson’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 Stefan G. Sandberg and Paul E.M. Phillips 4 Striatal Dendritic Adaptations in Parkinson’s Disease Models . . . . . 55 Michelle Day and D. James Surmeier 5 Diversity of Up-State Voltage Transitions During Different Network States. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 Nicolas Vautrelle, Luis Carrillo-Reid, and Jose´ Bargas 6 The Corticostriatal Pathway in Parkinson’s Disease . . . . . . . . . . . . . 87 Nigel S. Bamford and Carlos Cepeda 7 Cholinergic Interneuron and Parkinsonism. . . . . . . . . . . . . . . . . . . . . 105 Dario Cuomo, Paola Platania, Giuseppina Martella, Graziella Madeo, Giuseppe Sciamanna, Annalisa Tassone and Antonio Pisani 8 Basal Ganglia Network Synchronization in Animal Models of Parkinson’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117 Judith R. Walters and Debra A. Bergstrom v 9 Converging into a Unified Model of Parkinson’s Disease Pathophysiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143 Camila L. Zold, Mariano Belluscio, Fernando Kasanetz, Pablo E. Pomata, Luis A. Riquelme, Francois Gonon, and Mario Gustavo Murer 10 The Corticostriatal Transmission in Parkinsonian Animals: In Vivo Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157 Be´range`re Ballion, Nicolas Mallet, Catherine Le Moine, Mario Gustavo Murer, and Francois Gonon 11 Striatal Nitric Oxide–cGMP Signaling in an Animal Model of Parkinson’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171 Anthony R. West, Stephen Sammut, and Marjorie A. Ariano 12 Dopamine–Endocannabinoid Interactions in Parkinson’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185 Sarah McCallum and Joseph F. Cheer 13 Glutamate Plasticity in an Animal Model of Parkinson’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207 Charles K. Meshul Part III Computational Analyses of the Cortico-Subcortical Dynamics and Parkinson’s Disease 14 Neuromodulation and Neurodynamics of Striatal Inhibitory Networks: Implications for Parkinson’s Disease . . . . . . . . . . . . . . . . 233 Tomomi Shindou, Gordon W. Arbuthnott, and Jeffery R. Wickens 15 Dopaminergic Modulation of Corticostriatal Interactions and Implications for Parkinson’s Disease . . . . . . . . . . . . . . . . . . . . . . 245 John A. Wolf and Jason T. Moyer Part IV Neurobiology and Pathophysiology of Parkinson’s Disease 16 Pathogenesis of Oxidative Stress and the Destructive Cycle in the Substantia Nigra in Parkinson’s Disease . . . . . . . . . . . . . . . . . 261 Emilio Ferna´ndez-Espejo 17 Regulation of G-Protein-Coupled Receptor (GPCR) Trafficking in the Striatum in Parkinson’s Disease . . . . . . . . . . . . . . . . . . . . . . . . 273 Marie-Laure Martin-Negrier, Ce´line Guigoni, Bertrand Bloch, and Erwan Be´zard vi Contents 18 Atypical Parkinsonism in the French West Indies: The Plant Toxin Annonacin as a Potential Etiological Factor . . . . . . . . . . . . . . . . . . . Annie Lannuzel and Patrick Pierre Michel 19 Cognitive Deficits in Parkinson’s Disease. . . . . . . . . . . . . . . . . . . . . . Eliana Roldan Gerschcovich and Kuei Y. Tseng Part V Pharmacological and Non-Pharmacological Treatments in Parkinson’s Disease 20 Dopamine Replacement Therapy in Parkinson’s Disease: Past, Present and Future . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M.A. Cenci and P. Odin 21 Molecular, Cellular and Electrophysiological Changes Triggered by High-Frequency Stimulation of the Subthalamic Nucleus in Animal Models of Parkinson’s Disease. . . . . . . . . . . . . . . . . . . . . . Paolo Gubellini and Pascal Salin 22 Surgical Strategies for Parkinson’s Disease Based on Animal Model Data: GPi and STN Inactivation on Various Aspects of Behavior (Motor, Cognitive and Motivational Processes). . . . . . . Christelle Baunez 23 Antidromic Cortical Activity as the Source of Therapeutic Actions of Deep Brain Stimulation. . . . . . . . . . . . . . . . . . . . . . . . . . . Gordon W. Arbuthnott, Cyril Dejean, and Brian Hyland 24 Cell-Based Replacement Therapies for Parkinson’s Disease . . . . . . . Emilio Ferna´ndez-Espejo and Isabel Liste Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Contents vii 283 291 309 335 371 393 405